EUVIMEDEUVIMED entdecken
Crossref

Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement

Robert Becker, Mariah Rigsby, Mariko Suchi, Diana G Lerner, Ankur Chugh iD

Journal of Pediatric Gastroenterology and Nutrition · 2024-06 · 78 (6) · 1337-1341

DOI: 10.1002/jpn3.12187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 08.04.2024. Verfasst von Robert Becker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Division of Pediatric Gastroenterology, Medical College of Wisconsin/Children's Hos…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated patients aged 12–20 on dupilumab 300 mg weekly for treatment of eosinophilic esophagitis (EoE) who had ≥1 follow‐up endoscopy at a tertiary care pediatric hospital ( n = 18). Fifty percent had inflammatory EoE ( n = 9), 22% had fibrostenotic EoE ( n = 4), and 28% had non‐EoE eosinophilic gastrointestinal disease (EGID) with esophageal involvement ( n = 5). Ninety‐four percent discontinued topical corticosteroids (TCS) 2–4 weeks after starting dupilumab. Eighty‐nine percent of inflammatory EoE patients had histological response (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedHumansAdolescentMaleFemaleChildYoung AdultTreatment OutcomeEosinophiliaGastritisEsophagusEnteritisRetrospective Studies

Stichwörter der Autor:innen

corticosteroidsfibrostenoticfollow‐up endoscopypediatricweaning

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Division of Pediatric Gastroenterology, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Pediatric Gastroenterology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Pathology, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Ankur Chugh

Förderung

  • None

Zitieren

APA

Becker, R., Rigsby, M., Suchi, M., Lerner, D. G., & Chugh, A. (2024). Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement. Journal of Pediatric Gastroenterology and Nutrition, 78(6), 1337-1341. https://doi.org/10.1002/jpn3.12187

Vancouver

Becker R, Rigsby M, Suchi M, Lerner DG, Chugh A. Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(6):1337-1341. doi:10.1002/jpn3.12187

BibTeX
@article{Becker2024,
  author = {Becker, Robert and Rigsby, Mariah and Suchi, Mariko and Lerner, Diana G and Chugh, Ankur},
  title = {Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  volume = {78},
  number = {6},
  pages = {1337--1341},
  doi = {10.1002/jpn3.12187}
}
Kostenlos starten →